Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Enzyme-Linked Immunosorbent Assay01:33

Enzyme-Linked Immunosorbent Assay

19.4K
In 1971, Peter Perlman and Eva Engvall developed an Enzyme-linked immunosorbent assay (ELISA or EIA). ELISA differs from western blot in that the assays are conducted in microtiter plates or in vivo rather than on an absorbent membrane.
There are many different types of ELISAs, but they all involve an antibody molecule whose constant region binds an enzyme, leaving the variable region free to bind its specific antigen.  Enzyme-substrate reaction allows the antigen to be visualized or...
19.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The United Kingdom Branch Endoprosthesis for Aortic arch Treatment study (UK-BEAT): Early experience with the GORE TAG thoracic branch endoprosthesis.

Journal of vascular surgery·2026
Same author

Development and Clinical Validation of a Protocol-Agnostic Machine Learning Platform for Automated Treatment Planning in External Beam Radiation Therapy.

Advances in radiation oncology·2026
Same author

Tracking the evolution of medical students' clinical documentation skills: a pilot study leveraging a simulated electronic record and a longitudinal panel data analysis.

Frontiers in medicine·2026
Same author

A Return to the Logic-First Spirit of Corey's Retrosynthetic Analysis, Now Implemented in Modern Data-Driven CASP.

ACS central science·2026
Same author

Prevalence of monoclonal gammopathy of undetermined significance (MGUS) using a sensitive mass spectrometry assay in young individuals 10-49 years of age: a population-based study from the National Health and Nutritional Examination Survey.

Blood cancer journal·2026
Same author

<i>'Every Vape is a Hit to your Health'</i>: evaluation of an anti-vaping campaign in New South Wales, Australia.

Tobacco control·2026
Same journal

Functional Comparison of Neuronal Cells Differentiated from Human Induced Pluripotent Stem Cell-Derived Neural Stem Cells under Different Oxygen and Medium Conditions.

Journal of biomolecular screening·2017
Same journal

Development of an In Vitro Model to Screen CYP1B1-Targeted Anticancer Prodrugs.

Journal of biomolecular screening·2017
Same journal

Erratum.

Journal of biomolecular screening·2017
Same journal

Software, Database, and Information Services.

Journal of biomolecular screening·2017
Same journal

High-Throughput Platform for Identifying Molecular Factors Involved in Phenotypic Stabilization of Primary Human Hepatocytes In Vitro.

Journal of biomolecular screening·2016
Same journal

SLAS Europe High-Content Screening Conference in Dresden: A Glimpse of the Future?

Journal of biomolecular screening·2016
See all related articles

Related Experiment Video

Updated: Apr 19, 2026

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

11.1K

Using the BioAssay Ontology for analyzing high-throughput screening data.

Linda Zander Balderud1, David Murray2, Niklas Larsson3

  • 1Discovery Sciences, AstraZeneca R&D Mölndal, Mölndal, Sweden linda.zander-balderud@astrazeneca.com.

Journal of Biomolecular Screening
|December 17, 2014
PubMed
Summary
This summary is machine-generated.

BioAssay Ontology (BAO) 2.0 aids drug discovery by annotating high-throughput screening (HTS) data. This enables comparison of in-house and external assays, improving hit verification and method evaluation.

Keywords:
BioAssay OntologyPubChemassay designdetection technologyhigh-throughput screening

More Related Videos

High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

18.2K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.7K

Related Experiment Videos

Last Updated: Apr 19, 2026

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules
08:43

A Fluorescence-based Lymphocyte Assay Suitable for High-throughput Screening of Small Molecules

Published on: March 10, 2017

11.1K
High Content Screening in Neurodegenerative Diseases
13:32

High Content Screening in Neurodegenerative Diseases

Published on: January 6, 2012

18.2K
Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions
08:31

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

5.7K

Area of Science:

  • Drug discovery and development
  • Bioinformatics and cheminformatics
  • Assay development and validation

Background:

  • High-throughput screening (HTS) is crucial for hit identification in drug discovery.
  • A growing volume of screening data necessitates robust annotation and comparison methods.
  • The BioAssay Ontology (BAO) provides a standardized framework for assay description.

Purpose of the Study:

  • To utilize BAO 2.0 for annotating internal AstraZeneca HTS assays.
  • To enable systematic comparison between in-house and external screening data.
  • To identify technology gaps, evaluate new assay methods, and verify active hits.

Main Methods:

  • Application of BAO 2.0 for assay protocol annotation.
  • Analysis of annotated assays to compare in-house and external HTS data.
  • Case study: comparing in-house fluorescence intensity assay with external flow cytometry assay for FPR1 ligands.

Main Results:

  • BAO annotation facilitated identification and comparison of internal and external assays.
  • Twelve percent of compounds active in an in-house assay were also active in an external flow cytometry assay.
  • Demonstrated utility of BAO for evaluating assay effectiveness and identifying potential artifacts.

Conclusions:

  • BAO-driven assay annotation enhances the comparability of diverse HTS data.
  • Standardized annotation supports robust validation of drug discovery hits and assay methodologies.
  • Facilitates informed decisions in assay selection, optimization, and hit confirmation.